These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 34452561)
21. Differential interactions between GSTM1 and NAT2 genotypes on aromatic DNA adduct level and HPRT mutant frequency in lung cancer patients and population controls. Hou SM; Fält S; Yang K; Nyberg F; Pershagen G; Hemminki K; Lambert B Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):133-40. PubMed ID: 11219770 [TBL] [Abstract][Full Text] [Related]
23. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study. Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358 [TBL] [Abstract][Full Text] [Related]
24. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. Schroeder JC; Conway K; Li Y; Mistry K; Bell DA; Taylor JA Cancer Res; 2003 Nov; 63(21):7530-8. PubMed ID: 14612556 [TBL] [Abstract][Full Text] [Related]
25. Association of CYP1A1, CYP1A2, GSTM1 and NAT2 gene polymorphisms with colorectal cancer and smoking. Yoshida K; Osawa K; Kasahara M; Miyaishi A; Nakanishi K; Hayamizu S; Osawa Y; Tsutou A; Tabuchi Y; Shimada E; Tanaka K; Yamamoto M; Takahashi J Asian Pac J Cancer Prev; 2007; 8(3):438-44. PubMed ID: 18159984 [TBL] [Abstract][Full Text] [Related]
26. N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer. Lee KM; Park SK; Kim SU; Doll MA; Yoo KY; Ahn SH; Noh DY; Hirvonen A; Hein DW; Kang D Cancer Lett; 2003 Jul; 196(2):179-86. PubMed ID: 12860276 [TBL] [Abstract][Full Text] [Related]
27. NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. van der Hel OL; Peeters PH; Hein DW; Doll MA; Grobbee DE; Kromhout D; Bueno de Mesquita HB Pharmacogenetics; 2003 Jul; 13(7):399-407. PubMed ID: 12835615 [TBL] [Abstract][Full Text] [Related]
28. GSTM1 and NAT2 polymorphisms in operable and non-operable lung cancer patients. Hou SM; Ryberg D; Fält S; Deverill A; Tefre T; Børresen AL; Haugen A; Lambert B Carcinogenesis; 2000 Jan; 21(1):49-54. PubMed ID: 10607733 [TBL] [Abstract][Full Text] [Related]
29. Polymorphisms in xenobiotic conjugation and disease predisposition. Brockmöller J; Cascorbi I; Kerb R; Sachse C; Roots I Toxicol Lett; 1998 Dec; 102-103():173-83. PubMed ID: 10022251 [TBL] [Abstract][Full Text] [Related]
30. Modulation of DNA and protein adducts in smokers by genetic polymorphisms in GSTM1,GSTT1, NAT1 and NAT2. Godschalk RW; Dallinga JW; Wikman H; Risch A; Kleinjans JC; Bartsch H; Van Schooten FJ Pharmacogenetics; 2001 Jul; 11(5):389-98. PubMed ID: 11470992 [TBL] [Abstract][Full Text] [Related]
31. Do smoking and polymorphisms in xenobiotic metabolizing enzymes affect the histological stage and grade of bladder tumors? Ouerhani S; Rouissi K; Marrakchi R; Riadh Ben Slama M; Sfaxi M; Ayed M; Chebil M; Elgaaied A Bull Cancer; 2009 May; 96(5):E23-9. PubMed ID: 19467981 [TBL] [Abstract][Full Text] [Related]
32. Polymorphisms of glutathione-S-transferase and arylamine N-acetyltransferase enzymes and susceptibility to colorectal cancer. Kiss I; Németh A; Bogner B; Pajkos G; Orsós Z; Sándor J; Csejtey A; Faluhelyi Z; Rodler I; Ember I Anticancer Res; 2004; 24(6):3965-70. PubMed ID: 15736440 [TBL] [Abstract][Full Text] [Related]
33. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Taylor JA; Umbach DM; Stephens E; Castranio T; Paulson D; Robertson C; Mohler JL; Bell DA Cancer Res; 1998 Aug; 58(16):3603-10. PubMed ID: 9721868 [TBL] [Abstract][Full Text] [Related]
34. Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Hirvonen A; Pelin K; Tammilehto L; Karjalainen A; Mattson K; Linnainmaa K Cancer Res; 1995 Jul; 55(14):2981-3. PubMed ID: 7606714 [TBL] [Abstract][Full Text] [Related]
35. Genotype and allele frequencies of N-acetyltransferase 2 and glutathione S-transferase in the Iranian population. Torkaman-Boutorabi A; Hoormand M; Naghdi N; Bakhshayesh M; Milanian I Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1207-11. PubMed ID: 17880378 [TBL] [Abstract][Full Text] [Related]
36. N-Acetyltransferase 2, glutathione S-transferase gene polymorphisms and susceptibility to hepatocellular carcinoma in an Algerian population. Chorfi L; Fercha A; Derouiche F; Sebihi FZ; Houhou D; Chorfi K; Bendjemana K Xenobiotica; 2022 Jan; 52(1):99-104. PubMed ID: 35138223 [TBL] [Abstract][Full Text] [Related]
37. Gender-specific effects of NAT2 and GSTM1 in bladder cancer. Schnakenberg E; Lustig M; Breuer R; Werdin R; Hübotter R; Dreikorn K; Schloot W Clin Genet; 2000 Apr; 57(4):270-7. PubMed ID: 10845567 [TBL] [Abstract][Full Text] [Related]
38. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211 [TBL] [Abstract][Full Text] [Related]
39. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Brockmöller J; Cascorbi I; Kerb R; Roots I Cancer Res; 1996 Sep; 56(17):3915-25. PubMed ID: 8752158 [TBL] [Abstract][Full Text] [Related]
40. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility. Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S Urol Oncol; 2013 Oct; 31(7):1193-203. PubMed ID: 22154357 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]